vs

Side-by-side financial comparison of Emergent BioSolutions Inc. (EBS) and FULL HOUSE RESORTS INC (FLL). Click either name above to swap in a different company.

Emergent BioSolutions Inc. is the larger business by last-quarter revenue ($148.7M vs $75.4M, roughly 2.0× FULL HOUSE RESORTS INC). FULL HOUSE RESORTS INC runs the higher net margin — -16.4% vs -36.7%, a 20.3% gap on every dollar of revenue. On growth, FULL HOUSE RESORTS INC posted the faster year-over-year revenue change (3.4% vs -23.6%). Emergent BioSolutions Inc. produced more free cash flow last quarter ($73.8M vs $10.7M). Over the past eight quarters, FULL HOUSE RESORTS INC's revenue compounded faster (3.9% CAGR vs -29.6%).

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

Full House Resorts, Inc. is an American casino developer and operator based in Summerlin South, Nevada. The company currently operates five casinos. It is known for the involvement of Gulfstream Aerospace founder Allen Paulson, who was CEO from 1994 to 2000, and former Chrysler chairman Lee Iacocca, who was a major investor in the company from 1995 to 2013. Dan Lee has been CEO since late 2014.

EBS vs FLL — Head-to-Head

Bigger by revenue
EBS
EBS
2.0× larger
EBS
$148.7M
$75.4M
FLL
Growing faster (revenue YoY)
FLL
FLL
+27.0% gap
FLL
3.4%
-23.6%
EBS
Higher net margin
FLL
FLL
20.3% more per $
FLL
-16.4%
-36.7%
EBS
More free cash flow
EBS
EBS
$63.1M more FCF
EBS
$73.8M
$10.7M
FLL
Faster 2-yr revenue CAGR
FLL
FLL
Annualised
FLL
3.9%
-29.6%
EBS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EBS
EBS
FLL
FLL
Revenue
$148.7M
$75.4M
Net Profit
$-54.6M
$-12.4M
Gross Margin
42.9%
93.1%
Operating Margin
-18.8%
-1.3%
Net Margin
-36.7%
-16.4%
Revenue YoY
-23.6%
3.4%
Net Profit YoY
-74.4%
-0.6%
EPS (diluted)
$-0.95
$-0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EBS
EBS
FLL
FLL
Q4 25
$148.7M
$75.4M
Q3 25
$231.1M
$78.0M
Q2 25
$140.9M
$73.9M
Q1 25
$222.2M
$75.1M
Q4 24
$194.7M
$73.0M
Q3 24
$293.8M
$75.7M
Q2 24
$254.7M
$73.5M
Q1 24
$300.4M
$69.9M
Net Profit
EBS
EBS
FLL
FLL
Q4 25
$-54.6M
$-12.4M
Q3 25
$51.2M
$-7.7M
Q2 25
$-12.0M
$-10.4M
Q1 25
$68.0M
$-9.8M
Q4 24
$-31.3M
$-12.3M
Q3 24
$114.8M
$-8.5M
Q2 24
$-283.1M
$-8.6M
Q1 24
$9.0M
$-11.3M
Gross Margin
EBS
EBS
FLL
FLL
Q4 25
42.9%
93.1%
Q3 25
62.8%
93.2%
Q2 25
52.5%
93.5%
Q1 25
60.2%
93.4%
Q4 24
39.4%
92.1%
Q3 24
54.9%
92.2%
Q2 24
-18.8%
92.4%
Q1 24
49.2%
92.3%
Operating Margin
EBS
EBS
FLL
FLL
Q4 25
-18.8%
-1.3%
Q3 25
33.1%
4.4%
Q2 25
1.1%
-0.1%
Q1 25
22.5%
1.0%
Q4 24
-4.9%
-1.9%
Q3 24
22.0%
3.2%
Q2 24
-79.9%
3.2%
Q1 24
13.2%
-0.9%
Net Margin
EBS
EBS
FLL
FLL
Q4 25
-36.7%
-16.4%
Q3 25
22.2%
-9.8%
Q2 25
-8.5%
-14.0%
Q1 25
30.6%
-13.0%
Q4 24
-16.1%
-16.9%
Q3 24
39.1%
-11.2%
Q2 24
-111.2%
-11.7%
Q1 24
3.0%
-16.1%
EPS (diluted)
EBS
EBS
FLL
FLL
Q4 25
$-0.95
$-0.35
Q3 25
$0.91
$-0.21
Q2 25
$-0.22
$-0.29
Q1 25
$1.19
$-0.27
Q4 24
$-0.45
$-0.34
Q3 24
$2.06
$-0.24
Q2 24
$-5.38
$-0.25
Q1 24
$0.17
$-0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EBS
EBS
FLL
FLL
Cash + ST InvestmentsLiquidity on hand
$205.4M
$40.7M
Total DebtLower is stronger
$589.7M
$473.6M
Stockholders' EquityBook value
$522.6M
$2.5M
Total Assets
$1.3B
$649.8M
Debt / EquityLower = less leverage
1.13×
186.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EBS
EBS
FLL
FLL
Q4 25
$205.4M
$40.7M
Q3 25
$245.5M
$30.9M
Q2 25
$267.3M
$32.1M
Q1 25
$149.1M
$30.7M
Q4 24
$99.5M
$40.2M
Q3 24
$149.9M
$25.9M
Q2 24
$69.7M
$31.1M
Q1 24
$78.5M
$25.7M
Total Debt
EBS
EBS
FLL
FLL
Q4 25
$589.7M
$473.6M
Q3 25
$693.1M
$473.1M
Q2 25
$700.0M
$467.5M
Q1 25
$700.0M
$471.7M
Q4 24
$700.0M
$468.1M
Q3 24
$700.8M
$467.4M
Q2 24
$863.8M
$466.6M
Q1 24
$909.2M
$465.9M
Stockholders' Equity
EBS
EBS
FLL
FLL
Q4 25
$522.6M
$2.5M
Q3 25
$582.5M
$14.2M
Q2 25
$536.2M
$21.2M
Q1 25
$552.7M
$31.0M
Q4 24
$482.8M
$40.5M
Q3 24
$508.4M
$51.8M
Q2 24
$386.3M
$59.5M
Q1 24
$663.9M
$67.3M
Total Assets
EBS
EBS
FLL
FLL
Q4 25
$1.3B
$649.8M
Q3 25
$1.5B
$644.4M
Q2 25
$1.4B
$651.5M
Q1 25
$1.4B
$657.2M
Q4 24
$1.4B
$673.3M
Q3 24
$1.5B
$668.7M
Q2 24
$1.5B
$673.9M
Q1 24
$1.8B
$670.4M
Debt / Equity
EBS
EBS
FLL
FLL
Q4 25
1.13×
186.62×
Q3 25
1.19×
33.30×
Q2 25
1.31×
22.04×
Q1 25
1.27×
15.22×
Q4 24
1.45×
11.56×
Q3 24
1.38×
9.02×
Q2 24
2.24×
7.85×
Q1 24
1.37×
6.92×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EBS
EBS
FLL
FLL
Operating Cash FlowLast quarter
$77.7M
$12.0M
Free Cash FlowOCF − Capex
$73.8M
$10.7M
FCF MarginFCF / Revenue
49.6%
14.1%
Capex IntensityCapex / Revenue
2.6%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$156.8M
$-2.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EBS
EBS
FLL
FLL
Q4 25
$77.7M
$12.0M
Q3 25
$-2.3M
$-472.0K
Q2 25
$106.4M
$7.9M
Q1 25
$-11.2M
$-9.5M
Q4 24
$-79.9M
$14.8M
Q3 24
$153.7M
$-6.7M
Q2 24
$47.5M
$10.1M
Q1 24
$-62.6M
$-4.4M
Free Cash Flow
EBS
EBS
FLL
FLL
Q4 25
$73.8M
$10.7M
Q3 25
$-5.7M
$-5.5M
Q2 25
$103.5M
$4.5M
Q1 25
$-14.8M
$-12.3M
Q4 24
$-81.6M
$6.9M
Q3 24
$147.9M
$-17.4M
Q2 24
$42.9M
$-1.2M
Q1 24
$-73.4M
$-27.0M
FCF Margin
EBS
EBS
FLL
FLL
Q4 25
49.6%
14.1%
Q3 25
-2.5%
-7.1%
Q2 25
73.5%
6.1%
Q1 25
-6.7%
-16.4%
Q4 24
-41.9%
9.4%
Q3 24
50.3%
-23.0%
Q2 24
16.8%
-1.6%
Q1 24
-24.4%
-38.7%
Capex Intensity
EBS
EBS
FLL
FLL
Q4 25
2.6%
1.8%
Q3 25
1.5%
6.5%
Q2 25
2.1%
4.5%
Q1 25
1.6%
3.8%
Q4 24
0.9%
10.9%
Q3 24
2.0%
14.1%
Q2 24
1.8%
15.4%
Q1 24
3.6%
32.4%
Cash Conversion
EBS
EBS
FLL
FLL
Q4 25
Q3 25
-0.04×
Q2 25
Q1 25
-0.16×
Q4 24
Q3 24
1.34×
Q2 24
Q1 24
-6.96×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EBS
EBS

Medical Countermeasures MCM Product$99.2M67%
Commercial Products Segment$38.4M26%
All Other Revenue$11.1M7%

FLL
FLL

Midwest And South$58.2M77%
Food And Beverage$9.7M13%
Other Operations$3.6M5%
Other$2.3M3%
Contracted Sports Wagering$1.7M2%

Related Comparisons